Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 401–500 of 1,000
Glycans as Targets for Therapeutic Antitumor Antibodies
Rabu, C., McIntosh, R. S., Jurasova, Z., & Durrant, L. G. (2012) · Future Oncology · doi:10.2217/fon.12.88 · Cited by 54
Seif, A. E., Naranjo, A. H., Baker, D. L., Bunin, N., Kletzel, M., Kretschmar, C., Maris, J. M., McGrady, P., von Allmen, D., Cohn, S. L., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.276 · Cited by 50
Self-citationTreatment of High-Risk Neuroblastoma
Krystal, J. I., & Foster, J. H. (2023) · Children · doi:10.3390/children10081302 · Cited by 65
Jin, W., Zhang, Y., Zhao, Z., & Gao, M. (2024) · Theranostics · doi:10.7150/thno.93962 · Cited by 54
Targeting glycosphingolipids for cancer immunotherapy
Yu, J., Hung, J., Wang, S., Cheng, J., & Yu, A. L.-T. (2020) · FEBS Letters · doi:10.1002/1873-3468.13917 · Cited by 50
Self-citationRole of stemness-related molecules in neuroblastoma
Kamijo, T. (2012) · Pediatric Research · doi:10.1038/pr.2011.54 · Cited by 53
Yalçın, B., Kremer, L. C. M., Caron, H. N., & van Dalen, E. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub3 · Cited by 59
Paolo, D. D., Pastorino, F., Brignole, C., Corrias, M. V., Emionite, L., Cilli, M., Tamma, R., Priddy, L., Amaro, A. A., Ferrari, D., et al. (2020) · Small · doi:10.1002/smll.201906426 · Cited by 51
Self-citationAberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors
Matsumoto, Y., & Ju, T. (2023) · Cancers · doi:10.3390/cancers15143536 · Cited by 53
Seidel, D., Shibina, A., Siebert, N., Wels, W. S., Reynolds, C. P., Huebener, N., & Lode, H. N. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1669-5 · Cited by 48
“18 and adjuvant cytokines, significantly increased the 2-year event-free survival rate to 66 % compared to 46 % with 13-cis-retinoic acid alone [5].”
BackgroundSelf-citationDevelopment of treatment strategies for advanced neuroblastoma
Hara, J. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0417-5 · Cited by 56
“Major toxicities were neuropathic pain, capillary leak syndrome, and hypersensitivity reaction [36].”
Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma
Garner, E. F., & Beierle, E. A. (2015) · Cancers · doi:10.3390/cancers8010005 · Cited by 51
“Several immunotherapies are also being explored [5,71,81,96] (Figure 1).”
BackgroundDinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
Mora, J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1160775 · Cited by 49
“[34], and a pharmacokinetic analysis of 14 children [72] participating in the pivotal Phase 3 trial [67].”
BackgroundPatel, R. B., Baniel, C., Sriramaneni, R. N., Bradley, K. A., Markovina, S. T., & Morris, Z. S. (2018) · Brachytherapy · doi:10.1016/j.brachy.2018.07.004 · Cited by 49
Cheung, N. V., Ostrovnaya, I., Kuk, D., & Cheung, I. Y. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6777 · Cited by 49
Molecular profiling of childhood cancer: Biomarkers and novel therapies
Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., McCowage, G. B., Norris, M. D., & Byrne, J. A. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.06.003 · Cited by 53
“The use of anti-GD2 antibodies in combination with immunomodulators represents a major advance in the treatment of high-risk neuroblastoma, and the control of minimal residual disease [89,90].”
BackgroundWilliams, E. L., Dunn, S. N., James, S., Johnson, P., Cragg, M. S., Glennie, M. J., & Gray, J. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3226 · Cited by 47
“46%) in children who had received antiGD2–based immunotherapy in addition to standard highrisk neuroblastoma therapy (33).”
BackgroundLong‐term follow‐up of children with high‐risk neuroblastoma: The ENSG5 trial experience
Moreno, L., Vaidya, S. J., Pinkerton, R., Lewis, I. J., Imeson, J., Machin, D., Pearson, A. D. J., & on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG) (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24452 · Cited by 48
Hartomo, T. B., Pham, T. V. H., Yamamoto, N., Hirase, S., Hasegawa, D., Kosaka, Y., Matsuo, M., Hayakawa, A., Takeshima, Y., Iijima, K., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2801 · Cited by 51
Future of Clinical Genomics in Pediatric Oncology
Janeway, K. A., Place, A. E., Kieran, M. W., & Harris, M. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8470 · Cited by 48
“18, an anti-GD2 monoclonal antibody, in the high-risk population demonstrated improved survival in the group receiving the antibody.(119) Within T-cell ALL, the ETP-ALL subgroup has been identified as a patient population with a poor prognosis who may need intensified therapy.”
BackgroundCacciavillano, W., Sampor, C., Venier, C., Gabri, M. R., de Dávila, M. T. G., Galluzzo, L., Guthmann, M. D., Fainboim, L., Alonso, D. F., & Chantada, G. L. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25631 · Cited by 47
“[1,4] Among these, murine or humanized-murine chimeric monoclonal antibodies directed against GD2, a disialoganglioside have been reported and their use recently gained FDA approval.[5,6] However, anti-GD2 immunotherapy is a complex regimen that needs sophisticated infrastructurewhichmay not be available in most parts…”
BackgroundLin, J.-J., Huang, C., Yu, J., Liao, G., Lien, H., Hung, J., Lin, R., Chou, F., Yeh, K., & Yu, A. L.-T. (2014) · Breast Cancer Research · doi:10.1186/bcr3631 · Cited by 49
“The findings of GD2 as a CSC marker for PT and breast cancer have important therapeutic implication, in light of the recent success of anti-GD2 in the treatment of high risk neuroblastoma [43].”
BackgroundSelf-citationHoseini, S. S., Dobrenkov, K., Pankov, D., Xu, X. L., & Cheung, N. V. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320625 · Cited by 48
“Antibody based immunotherapies directed at this target have proven efficacy.(6,7) Cytotoxic effect of neuroblas-”
BackgroundLee, J. W., Lee, S., Cho, H. W., Ma, Y., Yoo, K. H., Sung, K. W., Koo, H. H., Cho, E. J., Lee, S., & Lim, D. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0477-0 · Cited by 47
Hishiki, T., Matsumoto, K., Ohira, M., Kamijo, T., Shichino, H., Kuroda, T., Yoneda, A., Soejima, T., Nakazawa, A., Takimoto, T., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1281-8 · Cited by 47
(2020) · PubMed Central · Cited by 47
Chu, Y., Nayyar, G., Jiang, S., Rosenblum, J., Soon‐Shiong, P., Safrit, J. T., Lee, D. A., & Cairo, M. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002267 · Cited by 52
Barnhill, L. M., Williams, R. T., Cohen, O., Kim, Y.-J., Batova, A., Mielke, J. A., Messer, K. S., Pu, M., Bao, L., Yu, A. L.-T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3447 · Cited by 46
“18 has resulted in significant decreases in relapse and a significant improvement in cure rate, almost one third of the children continue to fail therapy and succumb to the disease (18).”
InfluentialSelf-citationWeiss, B., Yanik, G. A., Naranjo, A. H., Zhang, F. F., Fitzgerald, W., Shulkin, B. L., Parisi, M. T., Russell, H. V., Grupp, S. A., Pater, L. E., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29117 · Cited by 46
“Median Curie score at diagnosis (range) 20 (0-28)b 17 (1-28) 20 (0-28)c”
Self-citationHill‐Kayser, C. E., Tochner, Z. A., Both, S., Lustig, R. A., Reilly, A. F., Balamuth, N., Womer, R. B., Maris, J. M., Grupp, S. A., & Bagatell, R. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24606 · Cited by 46
“18 has been shown to result in a 20% improvement in event-free survival in this population [3].”
BackgroundSelf-citationGlycobiology of Neuroblastoma: Impact on Tumor Behavior, Prognosis, and Therapeutic Strategies
Berois, N., & Osinaga, E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00114 · Cited by 50
“18, when combined with GM-CSF and interleukin-2, in high-risk NB patients, was associated with significantly improved survival compared to standard therapy after a 2-year follow-up period (171).”
Eschenburg, G., Eggert, A., Schramm, A. R., Lode, H. N., & Hundsdoerfer, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4072 · Cited by 55
“Despite intensive chemotherapy regimens, the prognosis of children with stage IV neuroblastoma is poor (1, 2).”
BackgroundMonterrubio, C., Paco, S., Olaciregui, N. G., Pascual‐Pasto, G., Vilà-Ubach, M., Cuadrado‐Vilanova, M., Ferrandiz, M. M., Castillo‐Ecija, H., Glisoni, R. J., Kuplennik, N., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.016 · Cited by 48
Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma
Krishnadas, D. K., Shapiro, T., & Lucas, K. G. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0376 · Cited by 46
Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells
Carpenter, E. L., Rader, J., Ruden, J. B., Rappaport, E. F., Hunter, K. N., Hallberg, P. L., Krytska, K., Oâ€TMDwyer, P. J., & Mossé, Y. P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00201 · Cited by 52
“18 monoclonal antibody targeting the disialoganglioside GD2, resulted in a dramatic increase in event-free survival from 46 to 66% (32).”
BackgroundMDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Barone, G., Tweddle, D., Shohet, J., Chesler, L., Moreno, L., Pearson, A., & Maerken, T. (2014) · Current Drug Targets · doi:10.2174/13894501113149990194 · Cited by 46
“18 anti-GD2, IL2 and GM-CSF to standard treatment has shown an increase in 2-year progressionfree survival to 60% and 2-year overall survival to 80% [19].”
BackgroundStructural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody
Horwacik, I., Golik, P., Grudnik, P., Kolinski, M., Zdzalik, M., Rokita, H., & Dubin, G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.052720 · Cited by 44
“This assumption is based on observations that naturally elevated levels of GD2-specific antibodies correlate with better prognosis [46] and the clinical success of passive immunization [7, 8].”
BackgroundMediastinal Masses in Children: Radiologic-Pathologic Correlation
Biko, D. M., Lichtenberger, J. P., Rapp, J. B., Khwaja, A. B., Huppmann, A. R., & Chung, E. M. (2021) · Radiographics · doi:10.1148/rg.2021200180 · Cited by 45
Bao, R., Spranger, S., Hernandez, K. M., Zha, Y., Pytel, P., Luke, J. J., Gajewski, T. F., Volchenboum, S. L., Cohn, S. L., & Desai, A. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002417 · Cited by 49
Self-citationCochonneau, D., Terme, M., Michaud, A., Dorvillius, M., Gautier, N., Frikeche, J., Alvarez-Rueda, N., Bougras-Cartron, G., Aubry, J., Paris, F., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.032 · Cited by 45
Immunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
“These findings paved the way for the Children’s Oncology Group ANBL0032 randomized phase III study in 2001, which examined the benefits of adding dinutuximab with GM-CSF and IL-2 to standard isotretinoin therapy in high-risk neuroblastoma patients [26].”
BackgroundT cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma
Singh, N., Kulikovskaya, I. M., Barrett, D. M., Binder-Scholl, G. K., Jakobsen, B. K., Martínez, D., Pawel, B., June, C. H., Kalos, M. D., & Grupp, S. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1040216 · Cited by 46
“This exhaustive regimen yields a three year event-free survival from diagnosis of only »45% of patients.(18,19) In addition, the outcome for relapsed neuroblastoma is very poor, with a current achievable goal of short-term disease control and very few patients who achieve longer-term remissions.”
BackgroundSelf-citationCheung, I. Y., Kushner, B. H., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1358331 · Cited by 47
“18 (dinutuximab, UnituxinTM) became the first IgG drug to receive FDA approval.(2) The current recommendation is to use dinutuximab in combination with cytokines granulocytemacrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2).”
BackgroundCavalli, E., Ciurleo, R., Petralia, M. C., Fagone, P., Bella, R., Mangano, K., Nicoletti, F., Bramanti, P., & Basile, M. S. (2020) · Molecules · doi:10.3390/molecules25051194 · Cited by 44
“In particular, the antidisialoganglioside (anti-GD2) immunotherapy has recently been successfully incorporated into the standard of care treatment for high-risk NB patients [8].”
BackgroundUpfront treatment of high‐risk neuroblastoma with a combination of 131 I‐MIBG and topotecan
Kraal, K. C. J. M., Tytgat, G. A. M., van Eck‐Smit, B. L. F., Kam, B. L. R., Caron, H. N., & van Noesel, M. M. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25580 · Cited by 44
“[3] Post-induction treatment with anti-disialoganglioside (GD2) directed immunotherapy [4] can increase the survival significantly.”
BackgroundTargetingO-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
Fleurence, J., Fougeray, S., Bahri, M., Cochonneau, D., Clemenceau, B., Paris, F., Heczey, A. A., & Birklé, S. (2017) · Journal of Immunology Research · doi:10.1155/2017/5604891 · Cited by 46
“…Ganglioside for Cancer Immunotherapy Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey, Stéphane Birklé To cite this version: Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, et al..…”
BackgroundInfluentialDesai, A. V., Fox, E., Smith, L. M., Lim, A. P., Maris, J. M., & Balis, F. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2575-9 · Cited by 47
“18 significantly improves survival in children with high-risk neuroblastoma [10].”
BackgroundMethodSelf-citationFisher, J. P. H., Flutter, B. R., Wesemann, F., Frosch, J., Rössig, C., Gustafsson, K. T., & Anderson, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1025194 · Cited by 43
Cheng, M. H., Santich, B. H., Xu, H., Ahmed, M., Huse, M., & Cheung, N. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168557 · Cited by 43
“Additionally, given its value as a TAA, several anti-GD2 monoclonal antibodies have been generated, with two already in the clinic treating patients with high-risk neuroblastoma,(10) and with one (UnituxinTM) getting FDA approval in the last year (March 2015).(30)”
BackgroundHo, M., Yu, A. L.-T., & Yu, J. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9715-x · Cited by 49
Self-citationCiccolini, J., Barbolosi, D., Meille, C., Lombard, A., Serdjebi, C., Giacometti, S., Padovani, L., Pasquier, E., & André, N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3130 · Cited by 45
“This is particularly relevant in neuroblastoma given the recent success of the combination of anti-GD2 antibody with IL2 therapy in this disease (42).”
BackgroundAnti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma
Wellens, L. M., Deken, M. M., Sier, C. F. M., Johnson, H. R., Ortiz, F. D. L. J., Bhairosingh, S. S., Houvast, R. D., Kholosy, W. M., Baart, V. M., Pieters, A. M. M. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74464-4 · Cited by 44
Cornel, A. M., Dünnebach, E., Hofman, D. A., Das, S., Sengupta, S., van den Ham, F., Wienke, J., Strijker, J. G. M., van den Beemt, D. A. M. H., Essing, A. H. W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005002 · Cited by 47
Marcucci, F., Bellone, M., Rumio, C., & Corti, A. (2013) · mAbs · doi:10.4161/mabs.22775 · Cited by 45
Visser, L. L., Bleijs, M., Margaritis, T., van de Wetering, M., Holstege, F. C. P., & Clevers, H. C. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0027 · Cited by 41
In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
Ahmed, M., Goldgur, Y., Hu, J., Guo, H.-F., & Cheung, N. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063359 · Cited by 42
“18 when combined with GMCSF and interleukin-2, was associated with a significantly improved survival in patients with high-risk neuroblastoma [3].”
BackgroundCarbohydrate Targets for CAR T Cells in Solid Childhood Cancers
Rössig, C., Kailayangiri, S., Jamitzky, S., & Altvater, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00513 · Cited by 43
“In a randomized phase III trial, the combined immunotherapeutic regimen resulted in significant increases of event-free and overall survival of high-risk neuroblastoma patients at 2 years (71).”
BackgroundMethodResultSu, Y., Qin, H., Chen, C., Wang, S., Zhang, S., Zhang, D., Jin, M., Peng, Y., He, L., Wang, X., et al. (2020) · Pediatric Investigation · doi:10.1002/ped4.12214 · Cited by 42
“02).(17) Another phase 3 randomized clinical trial of SIOPEN showed that the 5-year EFS rate was 53% and 5-year OS rate was 63% in patients with high-risk neuroblastoma who received anti-GD2 antibody ch14.”
BackgroundHingorani, P., Krailo, M., Buxton, A. B., Hutson, P. R., Sondel, P. M., Diccianni, M. B., Yu, A. L.-T., Morris, C. D., Womer, R. B., Crompton, B. D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.035 · Cited by 42
Self-citationThe Ionic Charge of Copper-64 Complexes Conjugated to an Engineered Antibody Affects Biodistribution
Dearling, J. L. J., Paterson, B. M., Akurathi, V., Betanzos-Lara, S., Treves, S. T., Voss, S. D., White, J. M., Huston, J. S., Smith, S. V., Donnelly, P. S., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00049 · Cited by 42
Remaining Challenges in Childhood Cancer and Newer Targeted Therapeutics
Smith, M. A., & Reaman, G. H. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.018 · Cited by 44
Self-citationLi, M., Liu, X., Zhao, Y., Ma, X., Zhou, Y., Zhao, Y., & Liu, X. (2019) · FEBS Journal · doi:10.1111/febs.15047 · Cited by 43
Monitoring Immune Responses in Neuroblastoma Patients during Therapy
Szanto, C. L., Cornel, A. M., Vijver, S. V., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12020519 · Cited by 45
“Even though immunotherapy increased 2-year EFS and OS [10], relapse is still observed in 40% of patients.”
BackgroundMoreno, L., Guo, D., Irwin, M. S., Berthold, F., Hogarty, M. D., Kamijo, T., Morgenstern, D. A., Pasqualini, C., Ash, S., Pötschger, U., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28794 · Cited by 41
Self-citationNeuroblastoma: The impact of biology and cooperation leading to personalized treatments
Owens, C., & Irwin, M. S. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2012.683483 · Cited by 48
Horwacik, I., Durbas, M., Boratyn, E., Węgrzyn, P., & Rokita, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.018 · Cited by 41
Kelly, L. M., Rutter, J. C., Lin, K., Ling, F., Duchmann, M., Latour, E., Arang, N., Pasquer, H., Ho‐Nhat, D., Charles, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00782-5 · Cited by 43
“Multiple successful anticancer therapies function by targeting lineage-specific survival factors 7–10 .”
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma
Pascual‐Pasto, G., McIntyre, B. C., Hines, M. G., Giudice, A. M., Garcia-Gerique, L., Hoffmann, J., Mishra, P., Matlaga, S., Lombardi, S., Shraim, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51337-2 · Cited by 41
“…the disialoganglioside GD2, a mammalian gly-colipid of neuroectodermal origin 16 , is now part of the standard of care for neuroblastoma patients 17,18 , with a mechanism of action reliant on engaging innate immune cells via their cell surface Fc-receptors (e.g., Fc γ RII and Fc γ RIII) to…”
BackgroundGubbels, J. A. A., Gadbaw, B., Buhtoiarov, I. N., Horibata, S., Kapur, A., Patel, D., Hank, J. A., Gillies, S. D., Sondel, P. M., Patankar, M. S., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1072-9 · Cited by 40
Self-citationTivnan, A., Heilinger, T., Ramsey, J. M., O’Connor, G., Pokorny, J. L., Sarkaria, J. N., Stringer, B. W., Day, B. W., Boyd, A., Kim, E. L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15073 · Cited by 42
“18 produced in SP2/0 cells) was approved for the treatment of neuroblastoma in combination with IL2 and GM-CSF [19].”
Moreno, L., Caron, H. N., Geoerger, B., Eggert, A., Schleiermacher, G., Brock, P. R., Valteau‐Couanet, D., Chesler, L., Schulte, J. H., Preter, K. D., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1340269 · Cited by 45
“Despite improvements in intensive multi-modal therapy, including chemotherapy, high-dose therapy with autologous hematopoietic stem cell rescue, surgical removal of the primary tumour, radiotherapy, residual disease therapy and immunotherapy with anti-GD2 monoclonal antibodies, long-term survival for children with hig…”
Pinto, N. R., DuBois, S. G., Marachelian, A., Diede, S. J., Taraseviciute, A., Bender, J. G., Tsao-Wei, D. D., Groshen, S. G., Reid, J. M., Haas-Kogan, D. A., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27023 · Cited by 42
Self-citationAdvances in neuroblastoma therapy
MacFarland, S. P., & Bagatell, R. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000711 · Cited by 43
van den Bijgaart, R. J. E., Kroesen, M., Wassink, M., Brok, I. C., Kers‐Rebel, E. D., Boon, L., Heise, T., van Scherpenzeel, M., Lefeber, D. J., Boltje, T. J., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002763 · Cited by 40
Nguyen, R., Moustaki, A., Norrie, J. L., Brown, S., Akers, W. J., Shirinifard, A., & Dyer, M. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1045 · Cited by 40
“Although nude mice have been previously utilized to model ADCC in neuroblastoma and led to the discovery of the monoclonal anti-GD2 antibody for therapeutic purposes (38), there are several limitations to this model system.”
Li, M., Sun, C., Bu, X., Que, Y., Zhang, L., Zhang, Y., Zhang, L., Lü, S., Huang, J., Zhu, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03894-3 · Cited by 42
“Although antiGD2-specific mAb immunotherapy has shown significant improvement in the outcome for high-risk NB patients [5, 6], the understanding of the molecular and genetic properties related to NB is still necessary for designing promising treatments for NB patients.”
BackgroundSchaafsma, E., Jiang, C., & Cheng, C. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.72 · Cited by 51
The biological role and immunotherapy of gangliosides and GD3 synthase in cancers
Cao, S., Hu, X., Ren, S., Wang, Y., Shao, Y., Wu, K., Yang, Z. F., Yang, W., He, G., & Li, X. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1076862 · Cited by 44
Carlson, L.-M., Geer, A. D., Sveinbjørnsson, B., Orrego, A., Martinsson, T., Kogner, P., & Levitskaya, J. (2013) · OncoImmunology · doi:10.4161/onci.23618 · Cited by 47
Besançon, O. G., Tytgat, G. A. M., Meinsma, R., Leen, R., Hoebink, J., Kalayda, G. V., Jaehde, U., Caron, H. N., & Kuilenburg, A. B. P. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.12.016 · Cited by 42
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
Targeting the myeloid microenvironment in neuroblastoma
Stip, M. C., Teeuwen, L., Dierselhuis, M. P., Leusen, J. H. W., & Krijgsman, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02913-9 · Cited by 43
“Both in vitro and in patients, the combination of GM-CSF with anti-GD2 antibodies activates neutrophils and upregulates CD11b expression [12, 123, 125, 126, 128].”
BackgroundThe Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Wisdom, A. J., Barker, C. A., Chang, J. Y., Demaria, S., Formenti, S. C., Grassberger, C., Gregucci, F., Hoppe, B. S., Kirsch, D. G., Marciscano, A. E. E., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.046 · Cited by 41
Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma
Ashraf, K., Shaikh, F., Gibson, P. J., Baruchel, S., & Irwin, M. S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24587 · Cited by 40
“In contrast, although single agent MIBG and anti-GD2 based immunotherapies have shown efficacy in patients following relapse and as part of upfront therapy, these treatments have limitations based on access and increased toxicities [29–31].”
BackgroundGrupp, S. A., Prak, E. T. L., Boyer, J., McDonald, K. R., Shusterman, S., Thompson, E. W., Callahan, C. A., Jawad, A. F., Levine, B. L., June, C. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1432 · Cited by 40
“Recently, anti-GD2 immunotherapy to treat minimal residual disease after achieving remission has led to additional improvements in survival; however, stem cell transplantation is considered standardof-care currently for high-risk patients (5, 6).”
Self-citationThe immune landscape of solid pediatric tumors
Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A. U. R., Saleh, A., Özer, E., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02397-z · Cited by 41
“In high-risk patients, complementing standard therapy with dinutuximab, which targets the NBL-associated antigen GD2, interleukin-2 (IL-2) and granulocyte-monocyte colonystimulating factor (GM-CSF) increased event-free and overall survival [22] but is not curative for the majority of patients who will ultimately relap…”
BackgroundEtoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies
Brown, B. S., Patanam, T., Mobli, K., Celia, C., Zage, P. E., Bean, A. J., & Tasciotti, E. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28875 · Cited by 39
“Specific liposomal binding The majority of anti-GD2 research focuses on GD2-positive or -negative cells, despite the potential clinical relevance of variable binding.(26,28,39) Quantitative assessment of targeting efficiency via flow cytometry revealed that GD2 expression was positively correlated with increased amoun…”
BackgroundDurbas, M., Horwacik, I., Boratyn, E., Kamycka, E., & Rokita, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3070 · Cited by 42
Emerging and investigational therapies for neuroblastoma
Applebaum, M. A., Desai, A. V., Bender, J. G., & Cohn, S. L. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1304212 · Cited by 39
“18 (dinutuximab) efficiently binds GD2 and culminated in the seminal COG ANBL0032 study which demonstrated that dinutuximab plus cytokines (GMS-CSF and IL-2) significantly improves EFS and OS [6].”
BackgroundSelf-citationKraal, K. C. J. M., Bleeker, G. M., van Eck‐Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N., & Tytgat, G. A. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.013 · Cited by 39
Elzembely, M. M., Dahlberg, A. E., Pinto, N. R., Leger, K. J., Chow, E. J., Park, J. R., Carpenter, P. A., & Baker, K. S. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27421 · Cited by 39
Cheung, I. Y., Mauguen, A., Modak, S. I., Ragupathi, G., Basu, E. M., Roberts, S. S., Kushner, B. H., & Cheung, N. V. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5999 · Cited by 38
Zhao, Q., Ahmed, M., Guo, H.-F., Cheung, I. Y., & Cheung, N. V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.650903 · Cited by 38
“Anti-GD2 antibodies are known to induce significantly painful side effects with occasional reports of cranial or peripheral neuropathy (7, 36).”
BackgroundCurrent and Potential Uses of Immunocytokines as Cancer Immunotherapy
Sondel, P. M., & Gillies, S. D. (2012) · Antibodies · doi:10.3390/antib1020149 · Cited by 38
Self-citationExploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
Casey, D. L., Lin, T.-Y., & Cheung, N. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00537 · Cited by 44
“A good example of the potential for immunotherapy in children is the use of anti-GD2 antibody in metastatic high risk neuroblastoma where cures beyond 10 years are now possible in the majority of patients without appreciable late effects from the anti-GD2 antibody (23, 24).”
BackgroundEukaryotic translation initiation factor 5A in the pathogenesis of cancers (Review)
Ning, L., Wang, L., Zhang, H., Jiao, X., & Chen, D. (2020) · Oncology Letters · doi:10.3892/ol.2020.11942 · Cited by 39
The Future of Childhood Cancer Survivorship
Dixon, S. B., Chow, E. J., Hjorth, L., Hudson, M. M., Kremer, L. C. M., Morton, L. M., Nathan, P. C., Ness, K. K., Oeffinger, K. C., & Armstrong, G. T. (2020) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2020.07.013 · Cited by 45
In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL
Kozani, P. S., Kozani, P. S., & O’Connor, R. S. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1089 · Cited by 40
Glycobiology of the Epithelial to Mesenchymal Transition
Pucci, M., Malagolini, N., & Dall’Olio, F. (2021) · Biomedicines · doi:10.3390/biomedicines9070770 · Cited by 40
Kholosy, W. M., Derieppe, M., van den Ham, F., Ober, K., Su, Y., Custers, L., Schild, L. G., van Zogchel, L. M. J., Wellens, L. M., Ariese, H. C., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090869 · Cited by 42
“Despite being poorly immunogenic epitopes, targeting ganglioside GD2 using anti-GD2 IgG MAbs in combination with interleukin-2 (IL-2), granulocyte-macrophage colonystimulating factor (GM-CSF) and 13-cis-retinoic acid resulted in a significant improvement in neuroblastoma patient survival [2,32].”
Background
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.